Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease (PRECISION-HD1)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03225833 |
|
Recruitment Status :
Recruiting
First Posted : July 21, 2017
Last Update Posted : February 8, 2021
|
Sponsor:
Wave Life Sciences Ltd.
Information provided by (Responsible Party):
Wave Life Sciences Ltd.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
PRECISION-HD1 is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of WVE-120101 in adult patients with early manifest Huntington's disease (HD) who carry a targeted single nucleotide polymorphism (SNP) rs362307 (SNP1).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Huntington's Disease | Drug: WVE-120101 Drug: Placebo | Phase 1 Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 60 participants |
| Allocation: | Randomized |
| Intervention Model: | Sequential Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients With Huntington's Disease |
| Actual Study Start Date : | July 17, 2017 |
| Estimated Primary Completion Date : | May 2021 |
| Estimated Study Completion Date : | May 2021 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Huntington disease
MedlinePlus related topics:
Huntington's Disease
| Arm | Intervention/treatment |
|---|---|
| Experimental: WVE-120101 (Dose A) or placebo |
Drug: WVE-120101
WVE-120101 is a stereopure antisense oligonucleotide (ASO) Drug: Placebo 0.9% Sodium Chloride |
| Experimental: WVE-120101 (Dose B) or placebo |
Drug: WVE-120101
WVE-120101 is a stereopure antisense oligonucleotide (ASO) Drug: Placebo 0.9% Sodium Chloride |
| Experimental: WVE-120101 (Dose C) or placebo |
Drug: WVE-120101
WVE-120101 is a stereopure antisense oligonucleotide (ASO) Drug: Placebo 0.9% Sodium Chloride |
| Experimental: WVE-120101 (Dose D) or placebo |
Drug: WVE-120101
WVE-120101 is a stereopure antisense oligonucleotide (ASO) Drug: Placebo 0.9% Sodium Chloride |
| Experimental: WVE-120101 (Dose E) or placebo |
Drug: WVE-120101
WVE-120101 is a stereopure antisense oligonucleotide (ASO) Drug: Placebo 0.9% Sodium Chloride |
Primary Outcome Measures :
- Safety: Number of patients with adverse events (AEs) [ Time Frame: Day 1 to Day 210 (end of study) ]All AEs reported or observed during the study, including AEs resulting from concurrent illnesses, reactions to concurrent medications, or progression of disease states
- Safety: Severity of AEs [ Time Frame: Day 1 to Day 210 (end of study) ]Severity will be evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
- Safety: Number of patients with serious AEs (SAEs) [ Time Frame: Day 1 to Day 210 (end of study) ]An SAE is defined as any event that results in death, is immediately life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect not present at Prescreening.
- Safety and Tolerability: Number of patients who withdraw due to AEs [ Time Frame: Day 1 to Day 210 (end of study) ]
Secondary Outcome Measures :
- Pharmacokinetics (PK): Maximum observed concentration (Cmax) [ Time Frame: Day 1 to Day 196 ]Cmax of WVE-120101 in plasma
- PK: Time of occurrence of Cmax (tmax) [ Time Frame: Day 1 to Day 196 ]tmax of WVE-120101 in plasma
- PK: Area under the plasma concentration-time curve (AUC 0-t) [ Time Frame: Day 1 to Day 196 ]AUC 0-t from time zero to the last quantifiable concentration of WVE-120101 in plasma
- PK: Terminal elimination rate constant [ Time Frame: Day 1 to Day 196 ]Elimination rate of WVE-120101 from plasma
- Pharmacodynamics (PD) [ Time Frame: Day 1 to Day 196 ]Concentration of mutant huntingtin (mHTT) protein in CSF
- Clinical Effects: Total Functional Capacity (TFC) [ Time Frame: Day 1 to Day 140 ]Change from baseline to the last measured time point (Day 140) and difference from placebo in the TFC, administered as part of the Unified Huntington's Disease Rating Scale (UHDRS).
Other Outcome Measures:
- UHDRS [ Time Frame: Day 1 to Day 140 ]Change from baseline to the last measured time point (Day 140) and difference from placebo in the UHDRS
- Short Problems Behavior Assessment (PBA-s) [ Time Frame: Day 1 to Day 140 ]Change from baseline to the last measured time point (Day 140) and difference from placebo in the PBA-s
- Magnetic Resonance Imaging [ Time Frame: Screening to Day 140 ]Changes from baseline MRI of the brain.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 25 Years to 65 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Key Inclusion Criteria:
- Prescreened with targeted SNP on the same allele as the pathogenic CAG expansion
- Ambulatory, male or female patients aged ≥25 - ≤65 years
- Clinical diagnostic motor features of HD, defined as Unified Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score = 4
- Early manifest HD, Stage I or Stage II based on UHDRS Total Functional Capacity Scores ≥7 and ≤13
Key Exclusion Criteria:
- Malignancy or received treatment for malignancy, other than treated basal cell or squamous cell carcinoma of the skin, within the previous 5 years.
- Received investigational drug or implantable device in prior 3 months or investigational oligonucleotide in prior 6 months or 5 half-lives of the oligonucleotide, whichever is longer
- Clinically significant medical condition, unstable psychiatric symptoms, substance abuse, or pregnancy
- Inability to undergo brain MRI
- Bone, spine, bleeding, or other disorder that exposes the patient to risk of injury or unsuccessful lumbar puncture
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03225833
Contacts
| Contact: Clinical Operations | 855-215-4687 | clinicaltrials@wavelifesci.com |
Locations
Show 21 study locations
Sponsors and Collaborators
Wave Life Sciences Ltd.
Investigators
| Study Director: | Medical Director, MD | Wave Life Sciences |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Wave Life Sciences Ltd. |
| ClinicalTrials.gov Identifier: | NCT03225833 |
| Other Study ID Numbers: |
WVE-HDSNP1-001 |
| First Posted: | July 21, 2017 Key Record Dates |
| Last Update Posted: | February 8, 2021 |
| Last Verified: | February 2021 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Huntington Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Movement Disorders Heredodegenerative Disorders, Nervous System Neurodegenerative Diseases |
Genetic Diseases, Inborn Cognition Disorders Neurocognitive Disorders Mental Disorders Dementia Chorea Dyskinesias |